Segro (LON:SGRO) Investors: JP Morgan Cazenove Reconfirms Underweight Rating, Sees GBX 670.00/Share; Xbiotech (XBIT) SI Decreased By 5.26%

XBiotech Inc. (NASDAQ:XBIT) Logo

JP Morgan Cazenove currently has a GBX 670.00 target price on the 6.37 billion GBP market cap company or 6.38% upside potential. In a research report revealed to investors on Monday morning, Segro (LON:SGRO) stock had its Underweight Rating maintained by professional analysts at JP Morgan Cazenove.

Xbiotech Inc (NASDAQ:XBIT) had a decrease of 5.26% in short interest. XBIT’s SI was 1.65 million shares in January as released by FINRA. Its down 5.26% from 1.74M shares previously. With 23,200 avg volume, 71 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 8.38%. The stock increased 2.87% or $0.17 during the last trading session, reaching $6.1. About 77,021 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 21, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $218.50 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: which released: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” on December 26, 2018, also with their article: “Bounce/Lag Momentum – Winning Stocks In A Market Downturn – Seeking Alpha” published on December 23, 2018, published: “EyePoint Pharmaceuticals and Sesen Bio among healthcare gainers; ZIOPHARM Oncology and Agenus among losers – Seeking Alpha” on December 26, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: and their article: “33 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” published on December 26, 2018 as well as‘s news article titled: “Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Benzinga” with publication date: December 21, 2018.

SEGRO plc, a real estate investment trust, engages in the acquisition, development, and management of commercial properties in Europe. The company has market cap of 6.37 billion GBP. The firm also provides utility services and services associated with such activities. It has a 5.64 P/E ratio. It also owns and manages flexible business space for various facilities in the areas of logistics, warehousing, other industrial facilities, offices, and retail.

More news for SEGRO Plc (LON:SGRO) were recently published by:, which released: “The 10,000 NJ Teachers Who Make $98K Or More In 2018 – Point Pleasant, NJ Patch” on December 03, 2018.‘s article titled: “Real estate transfers: Oct. 22-26 – Toledo Blade” and published on November 02, 2018 is yet another important article.

Among 8 analysts covering Segro (LON:SGRO), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Segro has GBX 745 highest and GBX 660 lowest target. GBX 712.38’s average target is 13.29% above currents GBX 628.8 stock price. Segro had 20 analyst reports since July 26, 2018 according to SRatingsIntel. The stock of SEGRO Plc (LON:SGRO) has “Hold” rating given on Wednesday, October 17 by Peel Hunt. Liberum Capital maintained the shares of SGRO in report on Monday, December 17 with “Buy” rating. The stock has “Buy” rating by Deutsche Bank on Tuesday, November 20. On Friday, October 12 the stock rating was maintained by Liberum Capital with “Buy”. The firm has “Underweight” rating given on Tuesday, October 16 by JP Morgan. Numis Securities downgraded the stock to “Hold” rating in Thursday, July 26 report. The stock of SEGRO Plc (LON:SGRO) has “Hold” rating given on Thursday, July 26 by Peel Hunt. The stock of SEGRO Plc (LON:SGRO) has “Buy” rating given on Wednesday, October 17 by Liberum Capital. The firm has “Hold” rating by Peel Hunt given on Friday, October 26. On Wednesday, December 12 the stock rating was maintained by Credit Suisse with “Outperform”.

The stock decreased 0.29% or GBX 1.8 during the last trading session, reaching GBX 628.8. About 143,246 shares traded. SEGRO Plc (LON:SGRO) has 0.00% since January 21, 2018 and is . It has by 0.00% the S&P500.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *